Stocktoria
Dianthus Therapeutics, Inc. /DE/ DNTH
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-06-21
Dianthus Therapeutics, Inc. /DE/ statistics & valuation
Market cap$5.2B
P / B10.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -8739.3% | -1633.7% | -1704.7% | — | — |
| Net margin | -7973.3% | -1362.8% | -1541.2% | — | — |
| Return on assets | -30.6% | -22.7% | -24.3% | -34.3% | -37.5% |
| Return on equity | -32.9% | -24.1% | -25.8% | 64.2% | 412.4% |
| Current ratio | 13.32 | 15.22 | 18.42 | 9.97 | 16.63 |
| Revenue growth | -67.3% | 120.6% | — | — | — |
Source: SEC EDGAR filings · CIK 0001690585 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.